The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...
Eli Lilly & Co.’s stock gained more than 2% on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes ...
Lilly announced that it will now sell Zepbound in vials, too. And a month's supply of vials with the 2.5 mg doses will cost ...
The makers of Zepbound are offering a massive price cut — if you're willing to purchase and dose your syringes out yourself.
1don MSN
The GLP-1 drug giant’s shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and ...
Lilly recently announced positive results from a pivotal clinical trial of Mounjaro that could lead to even stronger sales.
Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.
Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more.
The latest results from GLP-1 drugmaker Eli Lilly's clinical trial show that tirzepatide helped people maintain weight loss ...
While Mounjaro has no doubt been a monumental success, Lilly was also working on something else in the background. As Novo ...
Eli Lilly is cutting the cost of certain weight loss drugs, with new single-dose vials costing less than other medications ...
Eli Lilly says it will sell one-dose vials of Zepbound for roughly half the usual monthly list price. The weight loss drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results